<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204525">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000451</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAOMA12028</org_study_id>
    <secondary_id>R01AA012028</secondary_id>
    <nct_id>NCT00000451</nct_id>
  </id_info>
  <brief_title>Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)</brief_title>
  <official_title>Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in
      Alaska natives with alcohol dependence. The study will also examine whether a combination of
      naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used
      alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Days abstinent</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone plus Sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline</intervention_name>
    <description>16 week outpatient study</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone</intervention_name>
    <description>16 week outpatient study</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alaska Native having biological Alaska Native ancestry.

          -  Meets criteria for alcohol dependence.

          -  Prior to entering the study must be abstinent between 3 and 14 days and have a
             withdrawal assessment.

          -  Stable residence to ensure that subjects can be located during the study.

        Exclusion Criteria:

          -  Currently meets criteria for abuse or dependence on substances other than alcohol or
             nicotine.

          -  Current use of disulfiram.

          -  Psychotic or otherwise severely psychiatrically disabled.

          -  Use of other psychotropic medications including antidepressants and anxiolytics.

          -  Medical conditions that would not permit the use of sertraline or naltrexone, such as
             a history of unstable or severe hepatic, cardiovascular, metabolic, endocrine,
             gastrointestinal or kidney disease.

          -  Hepatocellular disease or elevated bilirubin levels.

          -  Females who are pregnant, nursing, or not using a reliable method of birth control.

          -  Probation or parole requirements that might interfere with participation in the
             study.

          -  Involvement in alcohol treatment other than provided by the study or AA.

          -  Use of monoamine oxidase inhibitors in the past month.

          -  Current use of Type 1C antiarrhythmics propafenone and flecainide.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Stephanie O'Malley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 28, 2013</lastchanged_date>
  <firstreceived_date>November 2, 1999</firstreceived_date>
  <keyword>Alcoholism</keyword>
  <keyword>Alcohol Dependence</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
